Drugs that contain Tofacitinib Citrate

1. Drug name - XELJANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(5 months from now)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PF PRISM CV Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PF PRISM CV Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1596257A PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

CN1325498C PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

IN241773B PF PRISM CV Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200200588P1 PF PRISM CV Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200401095P1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

IN251800B PF PRISM CV 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN218212B PF PRISM CV Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN200607324P1 PF PRISM CV 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

EP1382339A1 PF PRISM CV Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PF PRISM CV Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PF PRISM CV Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830B1 PF PRISM CV Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1451192B1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

EP1451192A1 PF PRISM CV Novel Crystalline Compound
Nov, 2022

(a month from now)

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

2. Drug name - XELJANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

IN241773B PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200200588P1 PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

EP1382339A1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PFIZER Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1235830B1 PFIZER Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG/ML BASE SOLUTION;ORAL Prescription

3. Drug name - XELJANZ XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(5 months from now)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1596257A PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

CN1325498C PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

IN241773B PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200200588P1 PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200401095P1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

IN251800B PFIZER 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN218212B PFIZER Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN200607324P1 PFIZER 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

EP1382339A1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PFIZER Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830B1 PFIZER Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1451192B1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

EP1451192A1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937181 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

US10639309 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 22MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.